Abstract
Next-generation sequencing (NGS) technologies allow for the generation of whole exome or whole genome sequencing data, which can be used to identify novel genetic alterations associated with defined phenotypes or to expedite discovery of functional variants for improved patient care. Because this robust technology has the ability to identify all mutations within a genome, incidental findings (IF)- genetic alterations associated with conditions or diseases unrelated to the patient’s present condition for which current tests are being performed- may have important clinical ramifications. The current debate among genetic scientists and clinicians focuses on the following questions: 1) should any IF be disclosed to patients, and 2) which IF should be disclosed – actionable mutations, variants of unknown significance, or all IF? Policies for disclosure of IF are being developed for when and how to convey these findings and whether adults, minors, or individuals unable to provide consent have the right to refuse receipt of IF. In this review, we detail current NGS technology platforms, discuss pressing issues regarding disclosure of IF, and how IF are currently being handled in prenatal, pediatric, and adult patients.
Keywords: Incidental findings, Next-generation sequencing, Disclosure, ACMG.
Current Genomics
Title:Management of Incidental Findings in the Era of Next-generation Sequencing
Volume: 16 Issue: 3
Author(s): Heather L. Blackburn, Bradley Schroeder, Clesson Turner, Craig D. Shriver, Darrell L. Ellsworth and Rachel E. Ellsworth
Affiliation:
Keywords: Incidental findings, Next-generation sequencing, Disclosure, ACMG.
Abstract: Next-generation sequencing (NGS) technologies allow for the generation of whole exome or whole genome sequencing data, which can be used to identify novel genetic alterations associated with defined phenotypes or to expedite discovery of functional variants for improved patient care. Because this robust technology has the ability to identify all mutations within a genome, incidental findings (IF)- genetic alterations associated with conditions or diseases unrelated to the patient’s present condition for which current tests are being performed- may have important clinical ramifications. The current debate among genetic scientists and clinicians focuses on the following questions: 1) should any IF be disclosed to patients, and 2) which IF should be disclosed – actionable mutations, variants of unknown significance, or all IF? Policies for disclosure of IF are being developed for when and how to convey these findings and whether adults, minors, or individuals unable to provide consent have the right to refuse receipt of IF. In this review, we detail current NGS technology platforms, discuss pressing issues regarding disclosure of IF, and how IF are currently being handled in prenatal, pediatric, and adult patients.
Export Options
About this article
Cite this article as:
L. Blackburn Heather, Schroeder Bradley, Turner Clesson, D. Shriver Craig, L. Ellsworth Darrell and E. Ellsworth Rachel, Management of Incidental Findings in the Era of Next-generation Sequencing, Current Genomics 2015; 16 (3) . https://dx.doi.org/10.2174/1389202916666150317232930
DOI https://dx.doi.org/10.2174/1389202916666150317232930 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Repositioning: A Unique Approach to Refurbish Drug Discovery
Current Drug Discovery Technologies Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews Obstructive Sleep Apnea Syndrome: From Phenotype to Genetic Basis
Current Genomics Screening, Evaluation, and Early Management of Acute Aortic Dissection in the ED
Current Cardiology Reviews Endovascular Repair of Thoracic Aortic Aneurysms
Recent Patents on Cardiovascular Drug Discovery Targeting Fibrosis in Systemic Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Multiple Aspects of Stroke and Stem Cell Therapy
Current Molecular Medicine Novel Biomarkers Assessing the Calcium Deposition in Coronary Artery Disease
Current Medicinal Chemistry Inflammaging and Proteases in Abdominal Aortic Aneurysm
Current Vascular Pharmacology Studies on Nonsense Mediated Decay Reveal Novel Therapeutic Options for Genetic Diseases
Recent Patents on DNA & Gene Sequences Management and Outcomes of Aortic Dissection in Pregnancy with Marfan Syndrome: A Systematic Review
Current Vascular Pharmacology Transforming Growth Factor-β Signaling in Motor Neuron Diseases
Current Molecular Medicine Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Chest Pain in Children
Current Pediatric Reviews Pediatrics for Disability: A Comprehensive Approach to Children with Syndromic Psychomotor Delay
Current Pediatric Reviews Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
Current Pharmaceutical Design The Usefulness of Phalangeal Quantitative Ultrasound in the Assessment of Skeletal Status in Children and Adolescents
Current Medical Imaging Role, Function and Therapeutic Potential of microRNAs in Vascular Aging
Current Vascular Pharmacology Intracranial Non-traumatic Aneurysms in Children and Adolescents
Current Pediatric Reviews